title: ABO-incompatible pediatric liver transplantation in very small recipients: Birmingham's experience.
abstract: Liver transplantation (LT) for very small recipients is challenging but in experienced centres, good results can be achieved. Despite the risk of antibody-mediated acute rejection, some studies have demonstrated the safety of ABO incompatible liver transplantation (ILT) in children and particularly in infants. The aim of our study was to describe the outcome of liver transplantation in infants <5 kg and the safety of using ILT in this group. All LT performed between 1991 and 2010 in children <5 kg were reviewed. Twenty-nine patients were included, five of whom had an ILT. Acute liver failure was encountered in 20 cases. The recipient age and weight at transplantation were respectively 63 days (range: 14-268 days) and 4 kg (range: 2.4-5 kg). The graft-to-recipient ratio was 6.1% (range 2.3-9%). An aortic conduit and delayed abdominal closure were used respectively in 76% and 81% of the procedures. The ABO compatible liver transplantation (CLT) and ILT groups were similar regarding recipient's demographics, graft types or technical transplantation data. The one- and five-yr patient and graft survival were respectively 62%, 62% and 62%, 57.9% with a median follow-up of 95 months. Vascular complications occurred in six cases (21.4%) and biliary complications were encountered in five patients (17%). Acute and chronic rejection developed respectively in 37% and 26% of the recipients. The five patients undergoing ILT are all alive without graft lost after a median follow-up of 34 months (range 7-55 months). When compared with the CLT group, no significant differences were found regarding patient or graft survival, vascular or biliary complications and rejection rates. In our experience, ILT in small infants has short and long term outcomes comparable to ABO-compatible grafts and excellent results can be achieved with a standard immunosuppressive protocol. To avoid mortality on the waiting list for neonatal recipients, ABO-incompatible liver grafts can be used safely.
authors.affiliation: Liver Unit, Birmingham Children's Hospital, Birmingham, UK. thomas.gelas@chu-lyon.fr
authors.forename: Thomas
authors.initials: T
authors.lastname: Gelas
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: McKiernan
authors.forename: Deirdre A
authors.initials: DA
authors.lastname: Kelly
authors.forename: David A
authors.initials: DA
authors.lastname: Mayer
authors.forename: Darius F
authors.initials: DF
authors.lastname: Mirza
authors.forename: Khalid
authors.initials: K
authors.lastname: Sharif
mesh_terms: D000017:ABO Blood-Group System / Q000276:immunology*; D000906:Antibodies / Q000737:chemistry; D001011:Aorta / Q000473:pathology; D001787:Blood Group Incompatibility; D002648:Child; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007231:Infant, Newborn; D017114:Liver Failure, Acute / Q000601:surgery; D016031:Liver Transplantation / Q000379:methods*; D008297:Male; D010372:Pediatrics / Q000379:methods*; D006113:United Kingdom
chemical_list: D000017:ABO Blood-Group System; D000906:Antibodies; D007166:Immunosuppressive Agents